CETRORELIX Drug Patent Profile
✉ Email this page to a colleague
When do Cetrorelix patents expire, and what generic alternatives are available?
Cetrorelix is a drug marketed by Teva Pharms Inc and is included in one NDA.
The generic ingredient in CETRORELIX is cetrorelix acetate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the cetrorelix acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cetrorelix
A generic version of CETRORELIX was approved as cetrorelix acetate by TEVA PHARMS INC on August 12th, 2022.
Summary for CETRORELIX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for CETRORELIX |
| DailyMed Link: | CETRORELIX at DailyMed |
Recent Clinical Trials for CETRORELIX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Beni-Suef University | Phase 2/Phase 3 |
| Bezmialem Vakif University | N/A |
| Zagazig University | N/A |
US Patents and Regulatory Information for CETRORELIX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Inc | CETRORELIX ACETATE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 215737-001 | Aug 12, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
